Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,710,000 shares, a growth of 1,022.5% from the December 15th total of 419,600 shares. Based on an average daily trading volume, of 6,840,000 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP lifted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the quarter. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 44.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners lowered their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Vincerx Pharma Stock Down 5.9 %

Shares of VINC opened at $0.18 on Tuesday. The stock has a market cap of $6.02 million, a P/E ratio of -0.17 and a beta of 1.48. The business’s 50 day moving average price is $0.25 and its 200-day moving average price is $0.49. Vincerx Pharma has a 52 week low of $0.18 and a 52 week high of $9.37.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.